U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H30N4O3.C4H4O4
Molecular Weight 538.5922
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of PNU-142633 MALEATE

SMILES

OC(=O)\C=C/C(O)=O.CNC(=O)C1=CC2=C(C=C1)[C@H](CCN3CCN(CC3)C4=CC=C(C=C4)C(N)=O)OCC2

InChI

InChIKey=GYOIZJALBHBRIJ-PCBAQXHCSA-N
InChI=1S/C24H30N4O3.C4H4O4/c1-26-24(30)19-4-7-21-18(16-19)9-15-31-22(21)8-10-27-11-13-28(14-12-27)20-5-2-17(3-6-20)23(25)29;5-3(6)1-2-4(7)8/h2-7,16,22H,8-15H2,1H3,(H2,25,29)(H,26,30);1-2H,(H,5,6)(H,7,8)/b;2-1-/t22-;/m0./s1

HIDE SMILES / InChI
Molecular Formula C24H30N4O3
Molecular Weight 422.52
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED
Molecular Formula C4H4O4
Molecular Weight 116.0722
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description

PNU-142633 is selective 5HT1D partial agonist, developed by Pharmacia & Upjohn, Inc. It failed in phase II clinical trials against acute migraine, and its development was discontinued.

CNS Activity

Originator

Pharmacia and Upjohn
22
Curator's Comment: Pharmacia was obtained by Pfizer.

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Partial Agonist
290
 4.6 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase II
1132
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
141 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/11595000
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PNU-142633 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
100 mg single, oral (unknown)
Highest studied dose
Dose: 100 mg
Route: oral
Route: single
Dose: 100 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/10543315
healthy
n = 6
Health Status: healthy
Sex: M+F
Food Status: UNKNOWN
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/10543315
Other AEs: Dizziness...
Other AEs:
Dizziness
Sources:
https://pubmed.ncbi.nlm.nih.gov/10543315
AEs

AEs

AESignificanceDosePopulation
Dizziness
100 mg single, oral (unknown)
Highest studied dose
Dose: 100 mg
Route: oral
Route: single
Dose: 100 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/10543315
healthy
n = 6
Health Status: healthy
Sex: M+F
Food Status: UNKNOWN
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/10543315
Sourcing

Sourcing

Vendor/AggregatorIDURL
Alfa Chemistry
11168
http://www.alfa-chemistry.com/search.aspx?q=11168
Alfa Chemistry
AFI187665652
http://www.alfa-chemistry.com/search.aspx?q=AFI187665652
ApexBio Technology
B6906
https://www.apexbt.com/catalogsearch/result/?q=B6906
BOC Sciences
187665-65-2
http://www.bocsci.com/description.asp?cas=187665-65-2
Chem Scene
CS-0024590
http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0024590
MedChem Express
HY-103131
https://www.medchemexpress.com/search.html?q=HY-103131&ft=&fa=&fp=
MolPort
MolPort-023-276-296
https://www.molport.com/shop/molecule-link/MolPort-023-276-296
MuseChem
M038152
https://www.musechem.com/product/M038152.html
Tocris
1985
https://www.tocris.com/search.php?Type=QuickSearch&Value=1985
Toronto Research Chemicals
P653455
https://www.trc-canada.com/product-detail/?CatNum=P653455
Wonderchem
WD05HDO
http://www.wonder-chem.com/search.html?text=WD05HDO
eMolecules
27315404
https://orderbb.emolecules.com/search/#?query=27315404
PubMed

PubMed

TitleDatePubMed
Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine.
2001 Sep
Patents

Patents

EP-0836599-A1
2
S-20140221385-A1
2

Sample Use Guides

In Vivo Use Guide
In phase II clinical trials patients received a single 50-mg oral dose of a 5-HT(1D) agonist, PNU-142633 during an acute migraine attack.
Route of Administration: Oral
In Vitro Use Guide
Receptor binding studies were performed on 5HT1D receptors, expressed in HEK293 cells. Binding of [3H]-serotonin was measured in membranes, using filtration techniques.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:47:06 GMT 2023
Edited
by admin
on Fri Dec 15 15:47:06 GMT 2023
Record UNII
VF98F3655P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PNU-142633 MALEATE
Common Name English
PNU-142633F
Common Name English
1H-2-BENZOPYRAN-6-CARBOXAMIDE, 1-(2-(4-(4-(AMINOCARBONYL)PHENYL)-1-PIPERAZINYL)ETHYL)-3,4-DIHYDRO-N-METHYL-, (1S)-, (2Z)-2-BUTENEDIOATE (1:1)
Systematic Name English
Code System Code Type Description
FDA UNII
VF98F3655P
Created by admin on Fri Dec 15 15:47:06 GMT 2023 , Edited by admin on Fri Dec 15 15:47:06 GMT 2023
PRIMARY
CAS
249765-69-3
Created by admin on Fri Dec 15 15:47:06 GMT 2023 , Edited by admin on Fri Dec 15 15:47:06 GMT 2023
PRIMARY
PUBCHEM
10052962
Created by admin on Fri Dec 15 15:47:06 GMT 2023 , Edited by admin on Fri Dec 15 15:47:06 GMT 2023
PRIMARY
Related Record Type Details
Structure of PNU-142633
PARENT -> SALT/SOLVATE
Structure of MALEIC ACID
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of PNU-142633
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966